Celgene Corporation  

(Public, NASDAQ:CELG)   Watch this stock  
Find more results for CELG
88.36
+0.72 (0.82%)
Real-time:   10:14AM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 87.15 - 88.52
52 week 65.76 - 90.50
Open 87.72
Vol / Avg. 464,503.00/5.11M
Mkt cap 35.38B
P/E 50.98
Div/yield     -
EPS 1.73
Shares 400.42M
Beta 1.15
Inst. own 163%
Oct 23, 2014
Q3 2014 Celgene Corp Earnings Release Add to calendar
Jul 24, 2014
Q2 2014 Celgene Corp. Earnings Release
Jul 24, 2014
Q2 2014 Celgene Corp Earnings Call
Jun 18, 2014
Celgene Corp. Annual Shareholder Meeting
Jun 11, 2014
Celgene Corp. at William Blair & Company LLC Growth Stock Conference
Jun 11, 2014
Celgene Corp. at Goldman Sachs Healthcare Conference
Jun 4, 2014
Celgene Corp. at Jefferies Global Healthcare Conference
May 29, 2014
Celgene Corp. at Sanford C Bernstein Strategic Decisions Conference
May 19, 2014
Celgene Corp. at UBS Global Healthcare Conference
May 13, 2014
Celgene Corp. at Bank of America Merrill Lynch Health Care Conference
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '14) 2013
Net profit margin 31.92% 22.33%
Operating margin 40.52% 27.86%
EBITD margin - 36.25%
Return on average assets - 11.55%
Return on average equity - 25.70%
Employees 5,100 -
CDP Score - 80 C

Address

86 MORRIS AVENUE
SUMMIT, NJ 07901
United States - Map
+1-908-6739000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Transcripts - SeekingAlpha

Description

Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases. It is engaged in the research and development, which is designed to bring new therapies to market, and is engaged in research in several scientific areas that may deliver therapies, focusing areas, such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases, and therapeutic application of cell therapies. Its primary commercial stage products include REVLIMID, VIDAZA, THALOMID, ABRAXANE and ISTODAX. Additional sources of revenue include a licensing agreement with Novartis, which entitles it to royalties on FOCALIN XR and the entire RITALIN family of drugs, the sale of services through its Cellular Therapeutics subsidiary and other miscellaneous licensing agreements. In March 2012, it acquired Avila Therapeutics.

Officers and directors

Robert J. Hugin Chairman of the Board, President, Chief Executive Officer
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark J. Alles President, Chief Operating Officer
Age: 55
Bio & Compensation  - Reuters
Jacqualyn A. Fouse Ph.D. President - Hematology & Oncology
Age: 52
Bio & Compensation  - Reuters
Scott Smith President - Inflammation & Immunology
Bio & Compensation  - Reuters
Perry A. Karsen Chief Operations Officer, Executive Vice President
Age: 59
Bio & Compensation  - Reuters
Lawrence V. Stein Executive Vice President, General Counsel, Corporate Secretary
Age: 64
Bio & Compensation  - Reuters
Thomas O. Daniel M.D. Executive Vice President, President - Research and Early Development
Age: 60
Bio & Compensation  - Reuters
Peter N. Kellogg Chief Financial Officer, Executive Vice President
Age: 58
Bio & Compensation  - Reuters
Michael D. Casey Lead Independent Director
Age: 68
Bio & Compensation  - Reuters
Richard W. Barker OBE Independent Director
Age: 65
Bio & Compensation  - Reuters